Literature DB >> 18614555

Pleural drainage and pleurodesis: implementation of guidelines in four hospitals.

J A Burgers1, P W A Kunst, M G J Koolen, L N A Willems, J S Burgers, M van den Heuvel.   

Abstract

The aim of the present study was to evaluate the implementation of the 2003 Dutch guideline on the diagnosis and treatment of malignant pleural effusions, and the potential effect of the implementation on the clinical outcome of pleurodesis. All patients with malignant pleural effusion who had a pleural drain placed with the intention of performing pleurodesis were registered prospectively in four centres. Details of the procedure and fluid recurrence and survival data were noted. Patients with a proven malignancy (n = 100) were entered into the registration database. Diagnostic guideline recommendations were followed in 60-70% of the patients. Surprisingly, pleurodesis was performed in only 75% of the patients, mainly due to the presence of a trapped lung. All pleurodeses were performed using talc, according to the guideline. Follow-up revealed fluid recurrence in 27 (36%) patients after a mean follow-up of 17 days (range 2-285 days); 14 patients with successful pleurodesis died with a median survival of 61 days (range 13-174 days). Systemic treatment following pleurodesis and good apposition of the pleural surfaces during drainage were good prognostic factors. Despite reasonable-to-good adherence to the guideline, the number of successful pleurodeses was low. Better predictors of a good pleurodesis outcome are needed.

Entities:  

Mesh:

Year:  2008        PMID: 18614555     DOI: 10.1183/09031936.00165607

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  11 in total

Review 1.  Switching off malignant pleural effusion formation-fantasy or future?

Authors:  Magda Spella; Anastasios D Giannou; Georgios T Stathopoulos
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

2.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

Review 3.  Malignant pleural effusion: tumor-host interactions unleashed.

Authors:  Georgios T Stathopoulos; Ioannis Kalomenidis
Journal:  Am J Respir Crit Care Med       Date:  2012-05-31       Impact factor: 21.405

4.  Mast cells mediate malignant pleural effusion formation.

Authors:  Anastasios D Giannou; Antonia Marazioti; Magda Spella; Nikolaos I Kanellakis; Hara Apostolopoulou; Ioannis Psallidas; Zeljko M Prijovich; Malamati Vreka; Dimitra E Zazara; Ioannis Lilis; Vassilios Papaleonidopoulos; Chrysoula A Kairi; Alexandra L Patmanidi; Ioanna Giopanou; Nikolitsa Spiropoulou; Vaggelis Harokopos; Vassilis Aidinis; Dionisios Spyratos; Stamatia Teliousi; Helen Papadaki; Stavros Taraviras; Linda A Snyder; Oliver Eickelberg; Dimitrios Kardamakis; Yoichiro Iwakura; Thorsten B Feyerabend; Hans-Reimer Rodewald; Ioannis Kalomenidis; Timothy S Blackwell; Theodora Agalioti; Georgios T Stathopoulos
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

5.  Specific effects of bortezomib against experimental malignant pleural effusion: a preclinical study.

Authors:  Ioannis Psallidas; Sophia P Karabela; Charalampos Moschos; Taylor P Sherrill; Androniki Kollintza; Sophia Magkouta; Panagiota Theodoropoulou; Charis Roussos; Timothy S Blackwell; Ioannis Kalomenidis; Georgios T Stathopoulos
Journal:  Mol Cancer       Date:  2010-03-10       Impact factor: 27.401

6.  Conventional versus pigtail chest tube-are they similar for treatment of malignant pleural effusions?

Authors:  Maria Aurora Mendes; Nuno China Pereira; Carla Ribeiro; Manuela Vanzeller; Teresa Shiang; Rita Gaio; Sérgio Campainha
Journal:  Support Care Cancer       Date:  2018-03-30       Impact factor: 3.603

Review 7.  The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion.

Authors:  Michael Bradshaw; Aaron Mansfield; Tobias Peikert
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

8.  Effectiveness and safety of outpatient pleurodesis in patients with recurrent malignant pleural effusion and low performance status.

Authors:  Ricardo Mingarini Terra; Lisete Ribeiro Teixeira; Benoit Jacques Bibas; Paulo Manuel Pego-Fernandes; Francisco Suso Vargas; Fabio Biscegli Jatene
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

9.  Beneficial impact of CCL2 and CCL12 neutralization on experimental malignant pleural effusion.

Authors:  Antonia Marazioti; Chrysoula A Kairi; Magda Spella; Anastasios D Giannou; Sophia Magkouta; Ioanna Giopanou; Vassilios Papaleonidopoulos; Ioannis Kalomenidis; Linda A Snyder; Dimitrios Kardamakis; Georgios T Stathopoulos
Journal:  PLoS One       Date:  2013-08-14       Impact factor: 3.240

10.  Icmt inhibition exerts anti-angiogenic and anti-hyperpermeability activities impeding malignant pleural effusion.

Authors:  Sophia Magkouta; Apostolos Pappas; Charalampos Moschos; Maria-Eleni Vazakidou; Katherina Psarra; Ioannis Kalomenidis
Journal:  Oncotarget       Date:  2016-04-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.